このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

多発性硬化症における生活の質に対する食事の有効性 (EDQ)

2026年9月15日 更新者:Terry L. Wahls

The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care. The primary objective of this study is to evaluate the effect of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for America), and the secondary objectives and the long-term effects on, motor function, low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain imaging.

調査の概要

詳細な説明

In the United States, MS affects nearly 1 million people with a 2.8:1 female to male ratio and the highest incidence rates among whites and African Americans. The economic cost of managing MS is substantial. In the U.S., the total medical costs for patients with MS increased from $116 million in 2002 to $198 million in 2013. MS is a chronic, neuroinflammatory, and neurodegenerative disease-causing symptoms of pain, fatigue, and changes in vision, cognition, and movement that greatly reduce quality of life (QoL) and the ability to maintain employment.

The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care. The primary objective of this study is to evaluate the effect of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for America), and the secondary objectives and the long-term effects on, motor function, low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain imaging.

The proposed study will consist of study participants attending 3 in-person site visits, months 0, 3, and 24, and online surveys every 3 months (months 0-24).

This study will use a randomized single-blind controlled design to test the short-term (6 months) and long-term (an additional 18 months) impact of the intervention diets on symptoms of MS including QoL and related outcomes stated above. We will use a fourteen-day run-in period to identify participants who are most likely to be successful in completing study procedures; this process has been effective in our previous studies. Participants who successfully complete all baseline self-reported outcomes and follow all study procedures during the seven-day run-in period will be scheduled for an on-site baseline visit for randomization to one of three diets (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination and Dietary Guidelines for America).

On-site study visits will include blood draws, motor, cognitive, vision function assessments, and MRI. Motor assessments will include a 6-minute walk test, 25-foot walk test, 9-hole pegboard to test hand function, symbol digit exercise to test thinking functions, and critical flicker fusion test, ocular coherence tomography and low contrast vision sensitivity to test vision. The study participant will be escorted to the MRI unit to complete a non-contrast MRI of the brain. At the baseline visit, participants will be randomized. Participants assigned to the intervention diets will be given intervention specific educational materials including shopping lists, example menus and recipes, and the study supplements. Study participants randomized to the dietary guidelines for Americans diet will receive emails and/or text messages (approximately 3-6 weeks) to receive resources with websites for the Dietary Guidelines of America, and recent multiple sclerosis-related research that does not involve diet.

Study team will provide fish oil, essential fatty acids, and phosphatidylcholine to the two intervention groups only. The participant will be scheduled for a Zoom video conference meeting with the assigned registered dietitian to review the assigned study diet.

In addition, subjects will collect saliva specimens for microbiome analysis at each of the 3 site study visits (months 0, 3 and 24).

Dietary History Questionnaire III will be completed at months 0, 3, 12 and 24 and will be used to assess adherence to the assigned dietary pattern.

The online questionnaires sent to participants every 3 months will also be used to track supplement intake, medication use, and details about health & life events, MS symptoms, fatigue, quality of life, doctor's appointment, and side effects they may be experiencing.

研究の種類

介入

入学 (実際)

162

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Iowa
      • Iowa City、Iowa、アメリカ、52246
        • Univeristy of Iowa

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~70年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Eligibility for the run-in phase of the study:

Participants will be eligible to enroll in the fourteen-day run-in phase of the study if they meet the following inclusion and exclusion criteria:

INCLUSION CRITERIA:

  • A definitive diagnosis of RRMS based on the 2017 revised McDonald Criteria.
  • The ability to prepare, or availability of someone to prepare, home-cooked meals.
  • Must own a computer, smartphone, or tablet device that has internet access to complete online surveys and capable of running study related applications.
  • Must be willing to follow study procedures outlined and explained to them.
  • Be between the ages of 18 to 70 at the time of consent.
  • Must be able to walk 25 feet without support.
  • Willingness to be randomized and follow any of the study diets.
  • Must consent to sharing the clinical notes from their primary care and neurology providers during the study period.

EXCLUSION CRITERIA:

  • Moderate or severe mental impairment.
  • Use of insulin, Coumadin, weight loss medications such as orlistat that causes fat malabsorption.
  • Worsening of symptoms resulting in the initiation or change of treatment including steroids (solumedrol, prednisone, etc.) or disease-modifying medications in 4 weeks prior to consent.
  • Treatment for cancer by radiation or chemotherapy in 12 months prior to consent, other than skin cancer.
  • Diagnosis of clinically significant heart disease, liver disease, kidney disease, or history of oxalate kidney stones.
  • Diagnosis of type II diabetes that does not have approval from treating physicians to adopt any of the 3 study diets.
  • Clinical diagnosis of moderate to severe psychiatric disease that makes study adherence more difficult (e.g., schizophrenia, bi-polar disease, severe depression and/or anxiety).
  • An active eating disorder such as anorexia, bulimia, binge eating, or orthorexia.
  • Measurement of BMI <20.
  • Confirmation of pregnancy or planning to become pregnant in the next 2 years.
  • History of diagnosed fat intolerance/malabsorption such as cholecystectomy or uncontrolled exocrine pancreatic insufficiency.
  • Participation in another research study investigating MS treatments, diet, or exercise.
  • Presence of a contraindication to completing a brain MRI or having claustrophobia which interferes with completion of MRI studies without the use of sedation.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Group 1 (Modified paleolithic elimination diet).

Modified paleolithic elimination diet.

nutraceutical supplement

他の名前:
  • リノール酸1400mg/リノレン酸350mg

nutraceutical supplement

他の名前:
  • エイコサペンタエン酸315mg/ドコサヘキサエン酸105mg

nutraceutical supplement

他の名前:
  • ホスファチジルコリン1300mg
  1. Complete elimination of all gluten-, dairy-, and egg-containing foods.
  2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.
  3. Consume 6-12 ounces/day protein including organ meats and fatty fish.
  4. Consume fermented foods daily.
  5. Consume daily servings of algae, seaweed, and nutritional yeast.
実験的:Group 2 (TROO)

Time Restricted Olive Oil Based (TROO) Ketogenic Diet

nutraceutical supplement

他の名前:
  • リノール酸1400mg/リノレン酸350mg

nutraceutical supplement

他の名前:
  • エイコサペンタエン酸315mg/ドコサヘキサエン酸105mg

nutraceutical supplement

他の名前:
  • ホスファチジルコリン1300mg
  1. Restriction of dietary carbohydrates to < 50 grams/day.
  2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to >160 grams/day.
  3. Consume <100 grams/day protein.
  4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).
  5. Consume at least 3 servings/day non-starchy vegetables.
アクティブコンパレータ:Group 3 Control

Usual diet with Dietary Guidelines for Americans Diet information

  1. Limit sodium to < 2,300 mg/day.
  2. Limit added sugar and saturated fat intake to <10% of kcal/day, respectively.
  3. Consume 5 servings of fruits and vegetables per day.
  4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.
  5. Consume 3 servings of reduced fat dairy per day.
  6. Consume 6 ounces/day protein foods.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
時間枠:baseline to 3 Months

Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

baseline to 3 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
時間枠:baseline to 6 Months

Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

baseline to 6 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
時間枠:baseline to 12 Months

Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

baseline to 12 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
時間枠:baseline to 18 Months

Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

baseline to 18 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
時間枠:baseline to 24 Months

Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

baseline to 24 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
時間枠:baseline to 3 Months

Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

baseline to 3 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
時間枠:baseline to 6 Months

Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

baseline to 6 Months

二次結果の測定

結果測定
メジャーの説明
時間枠
Modified Fatigue Impact Scale (MFIS)
時間枠:baseline to 3 months

Change in MFIS survey questions, scores range from 0-84, lower score is better.

baseline to 3 months
Modified Fatigue Impact Scale (MFIS)
時間枠:baseline to 6 months

Change in MFIS survey questions, scores range from 0-84, lower score is better.

baseline to 6 months
Modified Fatigue Impact Scale (MFIS)
時間枠:baseline to 12 months

Change in MFIS survey questions, scores range from 0-84, lower score is better.

baseline to 12 months
Modified Fatigue Impact Scale (MFIS)
時間枠:baseline to 18 months

Change in MFIS survey questions, scores range from 0-84, lower score is better.

baseline to 18 months
Modified Fatigue Impact Scale (MFIS)
時間枠:baseline to 24 months

Change in MFIS survey questions, scores range from 0-84, lower score is better.

baseline to 24 months
Hospital Anxiety Depression Scale (HADS)
時間枠:baseline to 3 months

Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence

baseline to 3 months
Hospital Anxiety Depression Scale (HADS)
時間枠:baseline to 6 months

Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence

baseline to 6 months
Hospital Anxiety Depression Scale (HADS)
時間枠:baseline to 12 months

Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence

baseline to 12 months
Hospital Anxiety Depression Scale (HADS)
時間枠:baseline to 18 months

Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence

baseline to 18 months
Hospital Anxiety Depression Scale (HADS)
時間枠:baseline to 24 months

Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence

baseline to 24 months
Fatigue Severity Scale score (FSS)
時間枠:Baseline to 3 months

Change in FSS survey question mean scores, scores range from 1-7, lower is better.

Baseline to 3 months
Fatigue Severity Scale score (FSS)
時間枠:Baseline to 6 months

Change in FSS survey question mean scores, scores range from 1-7, lower is better.

Baseline to 6 months
Fatigue Severity Scale score (FSS)
時間枠:Baseline to 12 months

Change in FSS survey question mean scores, scores range from 1-7, lower is better.

Baseline to 12 months
Fatigue Severity Scale score (FSS)
時間枠:Baseline to 18 months

Change in FSS survey question mean scores, scores range from 1-7, lower is better.

Baseline to 18 months
Fatigue Severity Scale score (FSS)
時間枠:Baseline to 24 months

Change in FSS survey question mean scores, scores range from 1-7, lower is better.

Baseline to 24 months
Brain volume as measured by non contrast magnetic resonance imaging (MRI)
時間枠:baseline to 24 months

Change in MRI grey matter brain volume, more is better

baseline to 24 months
Brain lesions as measured by non contrast magnetic resonance imaging (MRI)
時間枠:baseline to 24 months

Change in inflammatory lesions numbers as measured by non contrast brain MRI, fewer is better

baseline to 24 months
Timed 25 foot walk test
時間枠:baseline to 3 months

seconds required to walk 25 feet, lower is better

baseline to 3 months
Timed 25 foot walk test
時間枠:baseline to 24 months

seconds required to walk 25 feet, lower is better

baseline to 24 months
9 Hole peg board test
時間枠:baseline to 3 months

seconds require to move 9 pegs to various locations on a peg board, fewer seconds is better

baseline to 3 months
9 Hole peg board test
時間枠:baseline to 24 months

seconds require to move 9 pegs to various locations on a peg board, fewer seconds is better

baseline to 24 months
Low contrast visual acuity
時間枠:baseline to 3 months

A measure of best corrected vision, measure is log minimal angle of resolution at 2.5% contrast. Lower number is better.

baseline to 3 months
Low contrast visual acuity
時間枠:baseline to 24 months

A measure of best corrected vision, measure is log minimal angle of resolution at 2.5% contrast. Lower number is better.

baseline to 24 months
Dietary History Questionnaire IIi
時間枠:baseline to 12 months

Change in dietary intake measured by survey questions

baseline to 12 months
Dietary History Questionnaire IIi
時間枠:baseline to 3 months

Change in dietary intake measured by survey questions

baseline to 3 months
Critical flicker fusion
時間枠:baseline to 3 months

change in The herz at which a flickering light is seen as non-flickering as measured by herz

baseline to 3 months
Critical flicker fusion
時間枠:baseline to 24 months

change in The herz at which a flickering light is seen as non-flickering as measured by herz

baseline to 24 months
Ocular Coherence tomography
時間枠:baseline

Measure of optic nerve and retina depths using infrared light technology

baseline
Ocular Coherence tomography
時間枠:baseline to 3 months

change in the Measure of optic nerve and retina depths using infrared light technology

baseline to 3 months
Ocular Coherence tomography
時間枠:baseline to 24 months

change in the Measure of optic nerve and retina depths using infrared light technology

baseline to 24 months
Neurofilament light chain
時間枠:baseline to 3 months

blood biomarker of neuroaxonal (brain) damage

baseline to 3 months
Neurofilament light chain
時間枠:baseline to 24 months

blood biomarker of neuroaxonal (brain) damage

baseline to 24 months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
時間枠:baseline to 12 Months

Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

baseline to 12 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
時間枠:baseline to 18 Months

Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

baseline to 18 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
時間枠:baseline to 24 Months

Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

baseline to 24 Months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Terry L Wahls, MD、University of Iowa

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年2月10日

一次修了 (推定)

2026年10月1日

研究の完了 (推定)

2026年12月1日

試験登録日

最初に提出

2021年8月9日

QC基準を満たした最初の提出物

2021年8月13日

最初の投稿 (実際)

2021年8月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月18日

QC基準を満たした最後の更新が送信されました

2026年9月15日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Data that has been published will be shared if requested by a scientist conducting a PROSPERO registered meta-analyses who has signed a data use agreement with the University of Iowa Department of Sponsored Programs.

IPD 共有時間枠

One year after the specific data has been published.

IPD 共有アクセス基準

A scientist who has a PROSPERO registered meta-analysis whose meta-analysis protocol has been published. The scientist must contact the PI using their academic email, provide the published PROSPERO registered meta-analysis protocol manuscript, specify which data is being requested. Upon review of the submitted documents, the PI will initiated an outcoing material data use agreement with the Division of Sponsored Programs at the University of Iowa outlining the terms of use. After signing the approved contract, the data will be released to the requesting scientist.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する